@FiercePharma: Tops in FierceAnimalHealth: Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal. Story | Follow @FiercePharma
@EricPFierce: Ranbaxy's New Jersey plant comes through for drugmaker. More | Follow @EricPFierce
@CarlyHFierce: Our newest special report is live! Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce
> Pfizer ($PFE) CEO Ian Read says he hasn't given up on scoring a tax inversion deal, even with new U.S. rules designed to limit them; on a case-by-case basis, some might offer "meaningful value." Report
> India's generics maker Ranbaxy Laboratories posted its first profit since 2012, thanks to its generic version of the Novartis ($NVS) blood pressure med Diovan. Report
> India-based Lupin reported a 54% leap in quarterly profits, which beat analyst estimates; U.S. sales helped fuel revenue growth. Report
> Sanofi ($SNY) said it had started producing generic drugs in United Arab Emirates via Globalpharma, a UAE company now 66% owned by the French drugmaker. Report
Medical Device News
@FierceMedDev: IPOs: Sientra goes for $75M, while Nevro nerves up for $100M. Report | Follow @FierceMedDev
@VarunSaxena2: Here's my pernicious article. Read it are your own risk. ICYMI yesterday | Follow @VarunSaxena2
@EmilyWFierce: Find out which companies struck gold in the pharma M&A frenzy in FiercePharma's latest special report. Report | Follow @EmilyWFierce
> HealthTrust commits to buying Infraredx coronary imaging tech. Item
> Welch Allyn partners with startup Gentag to create wearable devices. More
> Wright, Tornier merge in $3.3B inversion deal to create extremities and biologics pure play. News
Biotech News
@FierceBiotech: $AMGN, $SNY and Ono band together for open-source R&D. Article | Follow @FierceBiotech
@JohnCFierce: Amgen adds up to 1,100 new job cuts to its global restructuring plan - Wall Street loves it, shares up 5%. News | Follow @JohnCFierce
@DamianFierce: $RNA CEO on $SRPT's setback: "We are all in this together." More from CNBC | Follow @DamianFierce
@EmilyMFierce: Salk's 100th: Anti-Vaccination Would Trouble Polio Hero. More from LiveScience | Follow @EmilyMFierce
> Novartis chief Jimenez predicts 'multi-blockbuster' success for star heart drug. Article
> Advent joins the parade of new biotech funds with $235M war chest. Item
> Receptos' lead drug scores another promising PhII--this time for ulcerative colitis. News
> Bristol-Myers nabs a HER2 cancer drug in $475M option deal with F-star. Report
Biotech Research News
> Government halts research on dangerous airborne pathogens. Item
> Toxin-producing stem cells designed to kill brain cell tumors. Report
> Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. Story
> Case Western, Janssen, Oncodesign scientists ID anti-inflammatory compounds. More
> Protein discovery could help kill stubborn latent HIV. Article
Pharma Manufacturing News
> Australia's CSL gets three Novartis vaccine plants in $275M deal. News
> Ranbaxy's New Jersey plant comes through for drugmaker. Item
> Hikma gets FDA warning letter for plant in Portugal. More
> Fujifilm adding Texas-based vaccine specialist to its fold. Story
> U.S. Attorney subpoenas Novo for info on Denmark plant. Article
And Finally...The FDA's staff reviewers recommended that Daiichi Sankyo's new blood thinner be approved, but with limits. Report